報價延遲最少15分鐘:2025/02/23 04:10 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.81 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.01/1.33
|
|
企業價值
816.91M
|
| 資產負債 |
|
每股賬面淨值
-1.95
|
| 現金流量 |
|
現金流量率
0.41
|
| 損益表 |
|
收益
442.74M
|
|
每股收益
2.67
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/02/23 04:10 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses,commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. |